Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Typically via subcutaneous injection per your provider's protocol
These tax-advantaged accounts have become a primary mechanism for healthcare purchasing, signaling a need for increased access to affordable solutions
Tirzepatide: This is a dual GIP/GLP-1 receptor agonist
Industry Funding: From the study, Eli Lilly and Company sponsored the work and was involved in the study design, data collection, data review, data analysis, and drafting of the report
US$ 20.98
US$ 24.60
US$ 20.08
US$ 25.81
US$ 26.00
US$ 25.38
